Department of Health and Human Services
National Institutes of Health
National Institute of Neurological Disorders and Stroke
National Advisory Neurological Disorders and Stroke Council
176th Meeting
September 17-18, 2009
Building 31, C Wing, 6th Floor, Conference Room 10
31 Center Drive
Bethesda, Maryland 20892
Contact Number at Meeting (301) 402-8710
September 17, 2009
Clinical Trials Subcommittee
Building 31, C Wing, Conference Room 10, Bethesda, Maryland
8:00 a.m. to 10:00 a.m.- Open Session
September 17, 2009
Basic and Preclinical Programs Subcommittee
Building 31, C Wing, Conference Room 7, Bethesda, Maryland
8:00 a.m. to 10:00 a.m.-Open Session
10:35 a.m.
II. Report of the Associate Director for Extramural Research, NINDS . . . . . . . Dr. Robert Finkelstein
Council Executive
Secretary
A. Consideration of Minutes of May 28-29, 2009, Meeting
B. Confirmation of Dates for Future Council Meetings
February 4-5, 2010 (Thursday and Friday)
May 27-28, 2010 (Thursday and Friday)
September 23-24, 2010 (Thursday and Friday)
February 3-4, 2011 (Thursday and Friday)
May 26-27, 2011 (Thursday and Friday)
September 15-16, 2011 (Thursday and Friday)
C. Other Items
Expedited Review Process
Loan Repayment Program
DER Announcements
10:45 a.m.
III. Report of the Director, NINDS . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . Dr. Story Landis
11:45 a.m. - Lunch
1:00 p.m.
IV. Concept Clearance for FY 2010 Proposed Initiatives . . . . . . . . . . . . . . . . . . . . . Dr. Finkelstein
1:30 p.m.
V. Update on the American Recovery and Reinvestment Act . . . . . . . . . Drs. Landis and Finkelstein
2:15 p.m. - Break
2:30 p.m.
VI. NIH Public-Private Partnerships
The Alzheimer's Disease Neuroimaging Initiative (ADNI): A Model for Public-Private
Partnership in Neuroscience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Dr. Richard Hodes
Director, National Institute
on Aging
Public-Private Partnerships with Rare Disease Communities . . . . . . . . . . . . . .Dr. Dan Tagle
Program
Director
Neurogenetics Cluster,
NINDS
Pharmacologic Bioequivalence between Generic and Brand Name Antiepileptic Drugs
in Patients with Epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dr. Brandy Fureman
Program
Director
Channels, Synapses & Circuits Cluster, NINDS
PPPs--Dos and Don'ts for Engaging Outside Partners . . . . . . . . . . . . Dr. Barbara Mittleman
Director, Program on Public-Private Partnerships
Office of Science Policy, Office of the Director,
NIH
4:00 p.m.
VII. Council Subcommittee Reports
Clinical Trials Subcommittee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Dr. Laura
Ment
NANDS Council
Member
Basic and Preclinical Programs Subcommittee . . . . . . . . . . . . . . . . . . . . Dr. John Povlishock
NANDS Council
Member
4:30 p.m.* *
Adjournment - September 17, 2009
8:00 a.m.
Closed Portion - September 18, 2009
*This portion of the meeting is being closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).
VIII. Review of Conflict of Interest, Confidentiality, and Council Procedures
Council Consideration of Pending Applications . . . . . . . . . . . . . . . . . . . . . . . Dr. Robert Finkelstein
11:30 a.m.**
Adjournment
**These times are tentative
Last updated January 6, 2011